Frequently Asked Questions
The market is segmented based on Global H1N1 (Swine Flu) Vaccination Market, By Vaccine Type (Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccines, Intramuscular, and Toxoid), Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip, and Others) and End User (Hospitals, Clinics, and Others) – Industry Trends and Forecast to 2030.
.
The Global H1n1 Swine Flu Vaccination Market size was valued at USD 13.29 USD Billion in 2022.
The Global H1n1 Swine Flu Vaccination Market is projected to grow at a CAGR of 6.2% during the forecast period of 2023 to 2030.
The major players operating in the market include Sanofi, Pfizer , GSK plc, Novartis AG, Mylan N.V., Baxter, AstraZeneca, Johnson & Johnson Private Limited, Virbac, Vetoquinol, Zoetis, Novavax, Zydus Group, Panacea Biotec, SINOVAC, Abbott, SEQIRUS, Cipla ,
-.
The market report covers data from the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
